米帕林盐酸盐
中文名称 | 米帕林盐酸盐 |
---|---|
中文同义词 | N4-(6-氯-2-甲氧基-9-吖啶基)-N1,N1-二乙基-1,4-戊二胺二盐酸盐二水合物;奎纳克林盐酸盐;米帕林盐酸盐;盐酸阿伯平;米帕林;奎纳克林二盐酸盐二水合物 |
英文名称 | Mepacrine hydrochloride |
英文同义词 | QUINACRINE DIHYDROCHLORIDE DIHYDRATE;QUINACRINE HYDROCHLORIDE, DIHYDRATE;6-chloro-9-((4-(diethylamino)-1-methylbutyl)amino)-2-methoxy-acridindihydr;6-chloro-9-((4-(diethylamino)-1-methylbutyl)amino)-2-methoxyacridinedihydroc;atabrinehydrochloridedihydrate;hloride2h2-o;mepacrinehcl;mepacrinehydrochloridedihydrate |
CAS号 | 6151-30-0 |
分子式 | C23H36Cl3N3O3 |
分子量 | 508.91 |
EINECS号 | |
相关类别 | 医药原料药-科研原料;医药原料;化学试剂 |
Mol文件 | 6151-30-0.mol |
结构式 |
米帕林盐酸盐 性质
熔点 | 247 °C |
---|---|
储存条件 | Store at -20°C |
溶解度 | DMSO:10mg/mL(19.65mM);; |
水溶解性 | 2.8 g/100 mL |
CAS 数据库 | 6151-30-0(CAS DataBase Reference) |
Quinacrine (5-20 μM; 24 hours) inhibits the growth of SGC-7901 cells.
Quinacrine (7.5 and 15 μM; 24 hours) induces apoptosis in SGC-7901 cells, which is associated with mitochondria-dependent signal pathway and involves p53 upregulation and caspase-3 activation pathway.
Quinacrine (15 μM; 24 hours) treatment significantly increased the levels of proapoptotic proteins, including cytochrome c, Bax, and p53, and decreased the levels of antiapoptotic protein Bcl-2, thus shifting the ratio of Bax/Bcl-2 in favor of apoptosis .
Cell Viability Assay
Cell Line: | SGC-7901 cells |
Concentration: | 0, 5, 10, 15, and 20 μM |
Incubation Time: | 24 hours |
Result: | Cell viability was inhibited in a dose-dependent manner, and the mean IC 50 value is 16.18 μM. |
Apoptosis Analysis
Cell Line: | SGC-7901 cells |
Concentration: | 7.5 and 15 μM |
Incubation Time: | 24 hours |
Result: | The percentage of apoptotic cells, including the early phase and late phase apoptosis, increased to 26.30%, compared with control group of 3.37%. |
Western Blot Analysis
Cell Line: | SGC-7901 cells |
Concentration: | 15 μM |
Incubation Time: | 24 hours |
Result: |
The relative quantity of cytochrome c protein was upregulated, increased from 0.10 to 0.24.
The relative quantity of p53 protein was dramatically increased, from 0.06 to 0.19. The Bax/Bcl-2 ratio was dramatically elevated from 1.21 to 2.59. |
Quinacrine (100 mg/kg three times per week for two consecutive weeks) significantly suppresses circulating blast cells at days 30/31 and increases the median survival time (MST). Quinacrine does not decrease the body weight of treated animals at the tested dose.
Animal Model: | Female SCID mice with acute myeloid leukemia (AML)-PS model |
Dosage: | 100 mg/kg |
Administration: | Administered by oral gavage (po); three times a week for two consecutive weeks |
Result: |
In the first AML mouse in vivo study, evaluation of circulating leukemic cells detected in blood samples (in percent of white blood cells (WBC)) at day 30/31 showed 72% human tumor cells in the control mice, whereas in mice treated with Quinacrine, this was only 2.2%.
The MST of control mice was 34 days whereas it was 46 days in Quinacrine-treated mice. |
安全信息
危险品标志 | Xn |
---|---|
危险类别码 | 22-36/37/38 |
安全说明 | 26-37/39 |
提供商 | 语言 |
---|---|
英文
|
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024/08/19 | S5435 | 米帕林盐酸盐 Quinacrine Dihydrochloride Dihydrate | 6151-30-0 | 25mg | 794.67元 |